Photo by dawson2406 from unsplash
Cost-effectiveness analysis of empagliflozin in comparison to liraglutide based on cardiovascular outcome trials Mark Lamotte1, Mafalda Ramos1, Ahmed Salem1, Volker Foos1, Anastasia Ustyugova2, Nikco Hau3, Pranav Gandhi4 1IQVIA Real World… Click to show full abstract
Cost-effectiveness analysis of empagliflozin in comparison to liraglutide based on cardiovascular outcome trials Mark Lamotte1, Mafalda Ramos1, Ahmed Salem1, Volker Foos1, Anastasia Ustyugova2, Nikco Hau3, Pranav Gandhi4 1IQVIA Real World Evidence Solutions, Zaventem, Belgium; 2Boehringer Ingelheim International GmbH, Ingelheim, Germany; 3Boehringer Ingelheim Ltd, Bracknell, UK; 4Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA.
Keywords:
empagliflozin comparison;
effectiveness analysis;
analysis empagliflozin;
liraglutide based;
comparison liraglutide;
cost effectiveness
Journal Title: Value in Health
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Value in Health
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!